719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers

oleh: Ignacio Garcia-Ribas, Maloy Ghosh, Anurag Tiwari, Sanghamitra Bhattacharjee, Yogendra Manjunath, Shalini Kashipathi, Subith Krishna, Ashvini Kumar Dubey, Tirtha Mandal, Soorya Gnanasegaran

Format: Article
Diterbitkan: BMJ Publishing Group 2023-11-01

Deskripsi

No description available for this item.